NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.410
-0.060 (-1.73%)
Sep 9, 2026, 11:58 AM EDT - Market open
NRx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 26.69 | 7.8 | 1.44 | 4.6 | 20.05 | 27.61 |
Cash & Short-Term Investments | 26.69 | 7.8 | 1.44 | 4.6 | 20.05 | 27.61 |
Cash Growth | 817.05% | 440.33% | -68.60% | -77.09% | -27.35% | 1384.94% |
Accounts Receivable | 0.21 | 0.16 | - | - | - | - |
Other Receivables | - | - | - | 0.01 | 0.01 | - |
Receivables | 0.21 | 0.16 | - | 0.01 | 0.01 | - |
Prepaid Expenses | 1.19 | 0.59 | 1.04 | 1.41 | 3.77 | 4.6 |
Other Current Assets | 1.08 | 0.34 | 0.82 | 0.87 | 1.97 | 0.51 |
Total Current Assets | 29.16 | 8.89 | 3.3 | 6.88 | 25.8 | 32.71 |
Property, Plant & Equipment | 1.75 | 0.7 | 0.01 | - | - | - |
Long-Term Investments | 0.4 | 0.4 | - | - | - | - |
Goodwill | 1.79 | 1.79 | - | - | - | - |
Other Intangible Assets | 0.83 | 0.93 | - | - | - | - |
Other Long-Term Assets | 0.22 | 0.25 | 0.34 | 0.43 | 0.02 | 0.02 |
Total Assets | 34.16 | 12.96 | 3.65 | 7.32 | 25.82 | 32.73 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.15 | 4.27 | 4.13 | 4.63 | 2.08 | 3.69 |
Accrued Expenses | 6.02 | 5.62 | 6.13 | 5.24 | 5.77 | 2.84 |
Current Portion of Long-Term Debt | - | - | 1.25 | 9.16 | 7.7 | 0.52 |
Current Portion of Leases | 0.38 | 0.32 | - | - | - | - |
Other Current Liabilities | 24.33 | 18.37 | 10.35 | 0.02 | 0.04 | 4.87 |
Total Current Liabilities | 33.87 | 28.58 | 21.86 | 19.05 | 15.59 | 11.92 |
Long-Term Debt | - | - | 5.01 | - | 2.82 | - |
Long-Term Leases | 0.46 | 0.32 | - | - | - | - |
Total Liabilities | 34.33 | 28.89 | 26.87 | 19.05 | 18.41 | 11.92 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.04 | 0.03 | 0.02 | 0.01 | 0.07 | 0.06 |
Additional Paid-In Capital | 324.63 | 290.93 | 255.04 | 241.41 | 230.34 | 203.99 |
Retained Earnings | -324.85 | -306.9 | -278.27 | -253.15 | -223 | -183.24 |
Comprehensive Income & Other | - | - | - | -0 | - | - |
Total Common Equity | -0.17 | -15.94 | -23.22 | -11.74 | 7.41 | 20.81 |
Shareholders' Equity | -0.17 | -15.94 | -23.22 | -11.73 | 7.41 | 20.81 |
Total Liabilities & Equity | 34.16 | 12.96 | 3.65 | 7.32 | 25.82 | 32.73 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.83 | 0.63 | 6.26 | 9.16 | 10.53 | 0.52 |
Net Cash (Debt) | 25.85 | 7.17 | -4.81 | -4.57 | 9.53 | 27.09 |
Net Cash Growth | - | - | - | - | -64.82% | 2450.57% |
Net Cash Per Share | 0.85 | 0.33 | -0.45 | -0.60 | 1.45 | 5.77 |
Filing Date Shares Outstanding | 43.26 | 33.03 | 16.92 | 9.45 | 7.06 | 6.66 |
Total Common Shares Outstanding | 43.12 | 31.7 | 14.59 | 8.27 | 6.54 | 5.88 |
Working Capital | -4.72 | -19.69 | -18.56 | -12.16 | 10.21 | 20.79 |
Book Value Per Share | -0.00 | -0.50 | -1.59 | -1.42 | 1.13 | 3.54 |
Tangible Book Value | -2.8 | -18.66 | -23.22 | -11.74 | 7.41 | 20.81 |
Tangible Book Value Per Share | -0.06 | -0.59 | -1.59 | -1.42 | 1.13 | 3.54 |
Machinery | 0.92 | 0.09 | 0.03 | - | - | - |